OmniaBio

Executive Summary

OmniaBio is a contract development and manufacturing organization (CDMO) headquartered in San Diego, California, specializing in cell and gene therapies. Founded in 2021, the company employs between 200 and 500 staff and provides process development and manufacturing services to biopharmaceutical clients. As a platform-stage private company, OmniaBio serves the rapidly growing cell and gene therapy market, which is expected to expand significantly as more therapies progress through clinical trials and toward commercialization. The company's position as a CDMO reduces its risk profile compared to drug developers, as it generates revenue through service fees rather than relying on product approvals. However, the competitive landscape includes established players like Lonza, Catalent, and Thermo Fisher Scientific. OmniaBio's focus on flexible, scalable manufacturing solutions positions it to capture demand from small and mid-size biotechs seeking outsourcing partners. Given its relatively recent founding, the company is likely investing in capacity expansion and technology platforms to differentiate itself.

Upcoming Catalysts (preview)

• Q3 2026Manufacturing capacity expansion announcement80% success
• H2 2026Key partnership with a late-stage cell therapy developer60% success